Volume 14, Issue 3 ( September 2022 2022)                   Iranian Journal of Blood and Cancer 2022, 14(3): 71-83 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Panahi M, Dehghani Ghorbi M, Amirpour M, Nayebi R, Kuhestani Dehaghi B H. Myelodysplastic Syndromes (MDS); diagnosis, classification, treatment and monitoring. Iranian Journal of Blood and Cancer 2022; 14 (3) :71-83
URL: http://ijbc.ir/article-1-1328-en.html
Myelodysplastic Syndromes (MDS); diagnosis, classification, treatment and monitoring
Maryam Panahi1 , Mahmoud Dehghani Ghorbi2 , Mozhgan Amirpour3 , Reika Nayebi4 , Bentol Hoda Kuhestani Dehaghi * 5
1- Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran
2- Department of hematology and oncology, school of allied medical sciences, Shahid Beheshti University of medical sciences, Tehran, Iran
3- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
4- Department of Hematology and Blood Banking, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
5- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. , Hodakuhestani@gmail.com
Abstract:   (959 Views)

Due to the neoplastic nature of myelodysplastic syndromes (MDS), they have been renamed as myelodysplastic neoplasms in the World Health Organization (WHO) 2022 classification. These syndromes are heterogeneous groups of myeloid disorders characterized by dysplasia of bone marrow cells, ineffective hematopoiesis, increased apoptosis, peripheral blood cytopenia, and risk of progression to acute myeloid leukemia (AML). The recent progress in understanding the pathogenesis of these diseases is due to the emergence of next-generation sequencing (NGS) and the simultaneous interpretation of
changes in cell morphologies, cytogenetics, and molecular mutations, which have provided the conditions for better classification and determination of efficient prognosis. Based on the Revised International Prognostic Scoring System (IPSS-R) system, MDS treatment approaches were divided into two groups: low-risk MDS, and high-risk MDS. In low-risk MDS, MDS is not the main cause of death, and most of the patients die as a result of cytopenia and the quality of life. Therefore, the goal of treatment approaches in low-risk MDS is to improve the quality of life in patients. However, in patients with high-risk MDS, the possibility of progression to AML is life-threatening. Therefore, clinical decisions aim to improve the course of the disease.
 

Keywords: Myelodysplastic syndromes, Low-risk MDS, High-risk MDS, Cytopenia
Full-Text [PDF 1956 kb]   (881 Downloads)    
: Review Article | Subject: Adults Hematology & Oncology
Received: 2022/12/14 | Accepted: 2023/01/29 | Published: 2023/02/19
References
1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. New England Journal of Medicine. 2009;361(19):1872-85. [DOI:10.1056/NEJMra0902908]
2. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D. Clinical effect of point mutations in myelodysplastic syndromes. New England Journal of Medicine. 2011;364(26):2496-506. [DOI:10.1056/NEJMoa1013343]
3. Yang L, Qian Y, Eksioglu E, Epling-Burnette PK, Wei S. The inflammatory microenvironment in MDS. Cellular and Molecular Life Sciences. 2015;72(10):1959-66. [DOI:10.1007/s00018-015-1846-x]
4. Shen J, Wang S, Zhang Y-J, Kappil MA, Wu H-C, Kibriya MG, Wang Q, Jasmine F, Ahsan H, Lee P-H. Genome-wide aberrant DNA methylation of microRNA host genes in hepatocellular carcinoma. Epigenetics. 2012;7(11):1230-7. [DOI:10.4161/epi.22140]
5. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C, Sekeres M, Saunthararajah Y, Maciejewski JP. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood, The Journal of the American Society of Hematology. 2009;113(6):1315-25. [DOI:10.1182/blood-2008-06-163246]
6. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBdO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720-48. [DOI:10.1038/s41375-022-01620-2]
7. Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, Haas R, Germing U. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leukemia research. 2011;35(12):1591-6. [DOI:10.1016/j.leukres.2011.06.001]
8. Drazer MW, Kadri S, Sukhanova M, Patil SA, West AH, Feurstein S, Calderon DA, Jones MF, Weipert CM, Daugherty CK. Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood advances. 2018;2(2):146-50. [DOI:10.1182/bloodadvances.2017013037]
9. Kündgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji R, Sekeres M, Della Porta M, Cazzola M, DeZern A, Roboz G. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia. 2021;35(3):835-49. [DOI:10.1038/s41375-020-0917-7]
10. Cargo CA, Rowbotham N, Evans PA, Barrans SL, Bowen DT, Crouch S, Jack AS. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood, The Journal of the American Society of Hematology. 2015;126(21):2362-5. [DOI:10.1182/blood-2015-08-663237]
11. Malcovati L, Gallì A, Travaglino E, Ambaglio I, Rizzo E, Molteni E, Elena C, Ferretti VV, Catricala S, Bono E. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood, The Journal of the American Society of Hematology. 2017;129(25):3371-8. [DOI:10.1182/blood-2017-01-763425]
12. Moreno Berggren D, Folkvaljon Y, Engvall M, Sundberg J, Lambe M, Antunovic P, Garelius H, Lorenz F, Nilsson L, Rasmussen B. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population‐based setting: a report from the Swedish MDS register. British journal of haematology. 2018;181(5):614-27. [DOI:10.1111/bjh.15243]
13. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, The Journal of the American Society of Hematology. 2016;127(20):2391-405. [DOI:10.1182/blood-2016-03-643544]
14. Alhan C, Westers T, Cremers E, Cali C, Witte B, Ossenkoppele G, Van De Loosdrecht A. The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system. Leukemia. 2016;30(3):658-65. [DOI:10.1038/leu.2015.295]
15. Duetz C, Westers TM, van de Loosdrecht AA. Clinical implication of multi-parameter flow cytometry in myelodysplastic syndromes. Pathobiology. 2019;86(1):14-23. [DOI:10.1159/000490727]
16. Valent P. ICUS, IDUS, CHIP and CCUS: diagnostic criteria, separation from MDS and clinical implications. Pathobiology. 2019;86(1):30-8. [DOI:10.1159/000489042]
17. Bejar R. CHIP, ICUS, CCUS and other four-letter words. Leukemia. 2017;31(9):1869-71. [DOI:10.1038/leu.2017.181]
18. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F. Revised international prognostic scoring system for myelodysplastic syndromes. Blood, The Journal of the American Society of Hematology. 2012;120(12):2454-65. [DOI:10.1182/blood-2012-03-420489]
19. Buesche G, Teoman H, Wilczak W, Ganser A, Hecker H, Wilkens L, Göhring G, Schlegelberger B, Bock O, Georgii A. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia. 2008;22(2):313-22. [DOI:10.1038/sj.leu.2405030]
20. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Kundgen A, Lübbert M, Kunzmann R, Giagounidis AA. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood, The Journal of the American Society of Hematology. 2007;110(13):4385-95. [DOI:10.1182/blood-2007-03-082404]
21. Boultwood J, Wainscoat JS. Gene silencing by DNA methylation in haematological malignancies. British journal of haematology. 2007;138(1):3-11. [DOI:10.1111/j.1365-2141.2007.06604.x]
22. Harnden DG. ISCN: An international system for human cytogenetic nomenclature. Cell Genet. 1985.
23. Haferlach C, Rieder H, Lillington DM, Dastugue N, Hagemeijer A, Harbott J, Stilgenbauer S, Knuutila S, Johansson B, Fonatsch C. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes, Chromosomes and Cancer. 2007;46(5):494-9. [DOI:10.1002/gcc.20433]
24. Sole F, Luno E, Sanzo C, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Cigudosa JC, Milla F, Ribera JM. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. haematologica. 2005;90(9):1168-78.
25. Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. Journal of clinical oncology. 2011;29(15):1963. [DOI:10.1200/JCO.2010.28.3978]
26. Valent P, Horny H-P, Bennett JM, Fonatsch C, Germing U, Greenberg P, Haferlach T, Haase D, Kolb H-J, Krieger O. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leukemia research. 2007;31(6):727-36. [DOI:10.1016/j.leukres.2006.11.009]
27. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton D, Gralnick H, Sultan C. Proposals for the classification of the myelodysplastic syndromes. British journal of haematology. 1982;51(2):189-99. [DOI:10.1111/j.1365-2141.1982.tb08475.x]
28. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood, The Journal of the American Society of Hematology. 2015;126(1):9-16. [DOI:10.1182/blood-2015-03-631747]
29. Wimazal F, Fonatsch C, Thalhammer R, Schwarzinger I, Müllauer L, Sperr WR, Bennett JM, Valent P. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leukemia research. 2007;31(11):1461-8. [DOI:10.1016/j.leukres.2007.03.015]
30. Valent P, Horny HP. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. European journal of clinical investigation. 2009;39(7):548-53. [DOI:10.1111/j.1365-2362.2009.02151.x]
31. Schroeder T, Ruf L, Bernhardt A, Hildebrandt B, Aivado M, Aul C, Gattermann N, Haas R, Germing U. Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. Annals of oncology. 2010;21(11):2267-71. [DOI:10.1093/annonc/mdq233]
32. Valent P, Bain BJ, Bennett JM, Wimazal F, Sperr WR, Mufti G, Horny H-P. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leukemia research. 2012;36(1):1-5. https://doi.org/10.1016/j.leukres.2014.09.010 [DOI:10.1016/j.leukres.2010.08.022]
33. Osman AE. When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)? Hematology. 2021;2021(1):399-404. [DOI:10.1182/hematology.2021000272]
34. Bewersdorf JP, Ardasheva A, Podoltsev NA, Singh A, Biancon G, Halene S, Zeidan AM. From clonal hematopoiesis to myeloid leukemia and what happens in between: will improved understanding lead to new therapeutic and preventive opportunities? Blood reviews. 2019;37:100587. [DOI:10.1016/j.blre.2019.100587]
35. Nachtkamp K, Stark R, Strupp C, Kündgen A, Giagounidis A, Aul C, Hildebrandt B, Haas R, Gattermann N, Germing U. Causes of death in 2877 patients with myelodysplastic syndromes. Annals of hematology. 2016;95(6):937-44. [DOI:10.1007/s00277-016-2649-3]
36. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S, Kantarjian H. Cause of death in patients with lower‐risk myelodysplastic syndrome. Cancer. 2010;116(9):2174-9. [DOI:10.1002/cncr.24984]
37. Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, Passamonti F, Invernizzi R, Castello A, Magrini U. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. Journal of clinical oncology. 2009;27(5):754-62. [DOI:10.1200/JCO.2008.18.2246]
38. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-9. [DOI:10.1038/nature10496]
39. Giesinger JM, La Nasa G, Sparano F, Angermeyer M, Morelli E, Mulas O, Efficace F, Caocci G. Health-related quality of life assessment in patients with myelodysplastic syndromes: evidence from randomized clinical trials. Clinical Practice and Epidemiology in Mental Health: CP & EMH. 2021;17(1):307. [DOI:10.2174/1745017902117010307]
40. De Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood, The Journal of the American Society of Hematology. 2017;129(13):1753-62. [DOI:10.1182/blood-2016-06-724500]
41. Thol F, Platzbecker U. Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS? Blood Advances. 2019;3(21):3449-53. [DOI:10.1182/bloodadvances.2018022434]
42. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood, The Journal of the American Society of Hematology. 2019;133(1):7-17. [DOI:10.1182/blood-2018-08-868752]
43. Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. The Lancet Haematology. 2019;6(6):e317-e27. [DOI:10.1016/S2352-3026(19)30029-8]
44. Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. The Lancet Haematology. 2019;6(4):e194-e203. [DOI:10.1016/S2352-3026(19)30030-4]
45. DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. New England Journal of Medicine. 2018;378(25):2386-98. [DOI:10.1056/NEJMoa1716984]
46. Pollyea DA, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, Frattini MG, Xu Q, Tosolini A, See WL. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019;33(11):2575-84. [DOI:10.1038/s41375-019-0472-2]
47. Prébet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, Dreyfus F, Rauzy OB, Recher C, Adès L. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. Journal of Clinical Oncology. 2011;29(24):3322. [DOI:10.1200/JCO.2011.35.8135]
48. Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. Journal of Clinical Oncology. 2017;35(24):2745. [DOI:10.1200/JCO.2015.66.2510]
49. Bahmani F, Azadpour S, Pourbagheri-Sigaroodi A, Bashash D. Plant-derived natural compounds as promising anticancer agents in hematological malignancies. Iranian Journal of Blood and Cancer. 2022;14(3):57-70.
50. Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby DL. CPX-351 versus 7+ 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. The Lancet Haematology. 2021;8(7):e481-e91. [DOI:10.1016/S2352-3026(21)00134-4]
51. Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA, Wang X, Kantarjian HM, Beran M. Comparison of idarubicin+ ara-C-, fludarabine+ ara-C-, and topotecan+ ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood, The Journal of the American Society of Hematology. 2001;98(13):3575-83. [DOI:10.1182/blood.V98.13.3575]
52. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. The lancet oncology. 2009;10(3):223-32. [DOI:10.1016/S1470-2045(09)70003-8]
53. Cheson BD, Simon R, editors. Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience. Seminars in Oncology; 1987.
54. Fenaux F. Cytogenetics are a predictive factor of response to low dose Ara-C in acute myelogenous leukemia (AML) in the elderly. Leukemia. 1990;4:312.
55. Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu Z-H, Spellman SR, Lee SJ. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. New England Journal of Medicine. 2017;376(6):536-47. [DOI:10.1056/NEJMoa1611604]
56. Brand R, Putter H, van Biezen A, Niederwieser D, Martino R, Mufti G, Onida F, Symeonidis A, Schmid C, Garderet L. Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data. PLoS One. 2013;8(10):e74368. [DOI:10.1371/journal.pone.0074368]
57. Fenaux P, Haase D, Sanz G, Santini V, Buske C. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology. 2014;25:iii57-iii69. [DOI:10.1093/annonc/mdu180]
58. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, Soiffer RJ, Antin JH. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109(10):4586-8. [DOI:10.1182/blood-2006-10-054924]
59. Jaekel N, Lieder K, Albrecht S, Leismann O, Hubert K, Bug G, Kröger N, Platzbecker U, Stadler M, De Haas K. Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2016;51(1):89-95. [DOI:10.1038/bmt.2015.204]
60. Platzbecker U. Treatment of MDS. Blood, The Journal of the American Society of Hematology. 2019;133(10):1096-107. [DOI:10.1182/blood-2018-10-844696]
61. Fenaux P, Rose C. Impact of iron overload in myelodysplastic syndromes. Blood reviews. 2009;23:S15-S9. [DOI:10.1016/S0268-960X(09)70005-0]
62. Österborg A, Brandberg Y. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2003;97(12):3125-6. [DOI:10.1002/cncr.11430]
63. Roy NB, Myerson S, Schuh AH, Bignell P, Patel R, Wainscoat JS, McGowan S, Marchi E, Atoyebi W, Littlewood T. Cardiac iron overload in transfusion‐dependent patients with myelodysplastic syndromes. British journal of haematology. 2011;154(4):521-4. [DOI:10.1111/j.1365-2141.2011.08749.x]
64. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, Coiteux V, Leroux G, Lepelley P, Daniel M-T. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood, The Journal of the American Society of Hematology. 2008;111(2):574-82. [DOI:10.1182/blood-2007-06-096370]
65. Jadersten M, Malcovati L, Dybedal I, Giovanni Della Porta M, Invernizzi R, Montgomery SM, Pascutto C, Porwit A, Cazzola M, Hellstrom-Lindberg E. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. Journal of Clinical Oncology. 2008;26(21):3607-13. [DOI:10.1200/JCO.2007.15.4906]
66. Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, Paietta E, Van Der Jagt R, Houston J, Thomas ML. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood, The Journal of the American Society of Hematology. 2009;114(12):2393-400. [DOI:10.1182/blood-2009-03-211797]
67. Golshayan AR, Jin T, Maciejewski J, Fu AZ, Bershadsky B, Kattan MW, Kalaycio ME, Sekeres MA. Efficacy of growth factors compared to other therapies for low‐risk myelodysplastic syndromes. British journal of haematology. 2007;137(2):125-32. [DOI:10.1111/j.1365-2141.2007.06546.x]
68. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, De Witte TM, Stone RM. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-25. [DOI:10.1182/blood-2005-10-4149]
69. Fenaux P, Santini V, Spiriti MAA, Giagounidis A, Schlag R, Radinoff A, Gercheva-Kyuchukova L, Anagnostopoulos A, Oliva EN, Symeonidis A. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. Leukemia. 2018;32(12):2648-58. [DOI:10.1038/s41375-018-0118-9]
70. Santini V, Schemenau J, Levis A, Balleari E, Sapena R, Ades L, Guerci A, Beyne-Rauzy O, Gourin M-P, Cheze S. Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? Blood, The Journal of the American Society of Hematology. 2013;122(13):2286-8. [DOI:10.1182/blood-2013-07-512442]
71. Jädersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Göhring G, Hedlund A, Hast R, Schlegelberger B, Porwit A. TP53 mutations in low-risk myelodysplastic syndromes with del (5q) predict disease progression. Journal of clinical oncology. 2011;29(15):1971-9. [DOI:10.1200/JCO.2010.31.8576]
72. Kelaidi C, Park S, Brechignac S, Mannone L, Vey N, Dombret H, Aljassem L, Stamatoullas A, Adès L, Giraudier S. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leukemia research. 2008;32(7):1049-53. [DOI:10.1016/j.leukres.2007.11.037]
73. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. New England Journal of Medicine. 2006;355(14):1456-65. [DOI:10.1056/NEJMoa061292]
74. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Cañizo C. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood, The Journal of the American Society of Hematology. 2011;118(14):3765-76. [DOI:10.1182/blood-2011-01-330126]
75. Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. Leukemia research. 2010;34(7):864-70. [DOI:10.1016/j.leukres.2009.12.004]
76. Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008;26(15):2505. [DOI:10.1200/JCO.2007.11.9214]
77. Lim Z, Killick S, Germing U, Cavenagh J, Culligan D, Bacigalupo A, Marsh J, Mufti G. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia. 2007;21(7):1436-41. [DOI:10.1038/sj.leu.2404747]
78. Stahl M, DeVeaux M, De Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood advances. 2018;2(14):1765-72. [DOI:10.1182/bloodadvances.2018019414]
79. Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett AJ. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 2003;102(8):3025-7. [DOI:10.1182/blood-2002-11-3325]
80. Komrokji R, Swern AS, Grinblatt D, Lyons RM, Tobiasson M, Silverman LR, Sayar H, Vij R, Fliss A, Tu N. Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies. The Oncologist. 2018;23(2):159-70. [DOI:10.1634/theoncologist.2017-0215]
81. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood, The Journal of the American Society of Hematology. 2008;111(1):86-93. [DOI:10.1182/blood-2007-01-068833]
82. Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del (5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. Journal of Clinical Oncology. 2016;34(25):2988-96. [DOI:10.1200/JCO.2015.66.0118]
83. Komrokji RS, List AF. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions. Hematology/Oncology Clinics. 2010;24(2):377-88. [DOI:10.1016/j.hoc.2010.02.013]
84. Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O. Luspatercept in patients with lower-risk myelodysplastic syndromes. New England Journal of Medicine. 2020;382(2):140-51. [DOI:10.1056/NEJMoa1908892]
85. Markham A. Luspatercept: first approval. Drugs. 2020;80(1):85-90. [DOI:10.1007/s40265-019-01251-5]
86. Hebbar M, Kaplan C, Caulier M, Wattel E, Morel P, Wetterwald M, Bauters F, Fenaux P. Low incidence of specific anti‐platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy. British journal of haematology. 1996;94(1):112-5. [DOI:10.1046/j.1365-2141.1996.6322262.x]
87. Bourgeois E, Caulier M, Rose C, Dupriez B, Bauters F, Fenaux P. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases. Leukemia. 2001;15(6):950-3. [DOI:10.1038/sj.leu.2402129]
88. Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. Journal of Clinical Oncology. 2010;28(3):437-44. [DOI:10.1200/JCO.2009.24.7999]
89. Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Carpenter N, Mehta B. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. The Lancet Haematology. 2018;5(3):e117-e26. [DOI:10.1016/S2352-3026(18)30016-4]
90. Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. The Lancet Haematology. 2017;4(3):e127-e36. [DOI:10.1016/S2352-3026(17)30012-1]
91. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 2004;104(1):263-9. [DOI:10.1182/blood-2003-08-2841]
92. Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montaňo Figueroa EH, Rodriguez MG, Dong X, Ghosh J, Izquierdo M. Iron Chelation in Transfusion-Dependent Patients With Low-to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. Annals of internal medicine. 2020;172(8):513-22. [DOI:10.7326/M19-0916]
93. Greenberg PL. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. Journal of the National Comprehensive Cancer Network. 2006;4(1):91-6. [DOI:10.6004/jnccn.2006.0010]
94. Platzbecker U, Kubasch AS, Homer-Bouthiette C, Prebet T. Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia. 2021;35(8):2182-98. [DOI:10.1038/s41375-021-01265-7]
95. Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel NK, Wolf D, Ringhoffer M, Czibere A, Nachtkamp K. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions-a retrospective multicenter analysis from the German Cooperative Transplant Study Group. Biology of Blood and Marrow Transplantation. 2015;21(4):653-60. [DOI:10.1016/j.bbmt.2014.12.016]
96. Roloff GW, Lai C, Hourigan CS, Dillon LW. Technical advances in the measurement of residual disease in acute myeloid leukemia. Journal of Clinical Medicine. 2017;6(9):87. [DOI:10.3390/jcm6090087]
97. Shapiro RM, Kim DDH. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome. Current Opinion in Hematology. 2018;25(6):425-32. [DOI:10.1097/MOH.0000000000000464]
98. Rautenberg C, Pechtel S, Hildebrandt B, Betz B, Dienst A, Nachtkamp K, Kondakci M, Geyh S, Wieczorek D, Haas R. Wilms' tumor 1 gene expression using a standardized european leukemianet-certified assay compared to other methods for detection of minimal residual disease in myelodysplastic syndrome and acute myelogenous leukemia after allogeneic blood stem cell transplantation. Biology of Blood and Marrow Transplantation. 2018;24(11):2337-43. [DOI:10.1016/j.bbmt.2018.05.011]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb